Unlike Zhao et al., who discussed a lower rate of MGMT promotor methylation as a possible reason for the poorer prognosis of SVZ-involving gliomas, we did not find significant differences in MGMT promotor methylation between SVZ-contacting and non-contacting tumors. The gene discussed is MGMT; the disease is central nervous system cancer.